Every year, National Cancer Institute partners with CDC, American Cancer Society, and NAACCR, Inc. to produce the Annual Report to the Nation on the Status of Cancer.

This year’s report shows cancer deaths continued a downward trend between 2015-2019. #CancerAnnualReport bit.ly/3EUrClc

Opinion | The UK's new Prime Minster is the child of Indian immigrants. Is it tine to admit that colonialism worked?

by Bret Stephens

BREAKING NEWS:
The 2022 #NobelPrize in Physiology or Medicine has been awarded to Svante Pääbo “for his discoveries concerning the genomes of extinct hominins and human evolution.”

Wow.

First randomized study to show TIL improves PFS vs ipi in advanced melanoma. Congrats to J Haanen and team!
#ESMO2022
esmo.org/newsroom/press…

A breakthrough by Swanton Lab
in understanding emergence of lung cancer in never-smokers 🚭

Breathing in PM2.5 pollution ➡️ inflammatory IL1B release ➡️ tumor formation 🫁

Anti-IL1B drug prevented cancer from forming in mice exposed to air pollution 🐭
bbc.com/news/health-62…

CAR-T folks, how often is CAR-T dysfunction a problem in *clinical* responses against hematologic malignancies? My sense is that antigen loss (e.g.CD19) is the dominant resistance issue ? Pls point to some studies if possible. Thx.

This is a big deal.

Today, we are moving to make America's federally funded research freely accessible to the American public without delay. These changes will save lives & spur innovation in clean energy, cancer breakthroughs, environmental justice, and more.

Learn more ⤵️whitehouse.gov/ostp/news-upda…

Like many of you, I'm thinking about Salman Rushdie now.

The threat he has lived under for so long–which was so horrifically realized today–was the product, not merely of the hatred and zeal of religious fanatics...

All of us NCI Center for Cancer Research are very much looking forward to working with Dr. Monica Bertagnolli Monica Bertagnolli to continue to bring our unique approach to cancer research to all patients and the cancer community. Welcome to @NCI. whitehouse.gov/briefing-room/… via @whitehouse

A library of mutant p53–reactive TCRs is established. Read here on how this library can be used in the treatment of patients with cancer; by Kim, Rosenberg et al.
bit.ly/3OXvK5x
Sri Krishna Frank Noam Stephanie L Goff, MD, FACS Anup Parikh, MD #CIRReviewerStar ⭐

We applied mutational signature based-models to identify patients with functional POLE/D1 mutations. Up to 75% of these patients benefited from immunotherapy in our cohort. The mutation processes shape the biochemical landscape of neoantigens. Check out more Nature Genetics 👇👇👇

The P53 (R175H) hotspot mutation is broadly immunogenic in HLA-A*02:01+ cancer patients and is now validated as a human cancer rejection antigen using #TCR gene therapy. Excellent work by Kim and colleagues from the Surgery Branch.

Can p53 hotspot mutations generate immunogenic HLA-I neoantigens? Yes, they can. Very nice experimental data by Peter Kim and Steven Rosenberg et al.

Sri Krishna The recent report you refer to was based largely on in silico predictions. The authors of that report have not been able to articulate how these empiric data demonstrating that the R175H hotspot is a bona fide cancer rejection antigen can be reconciled with their predictions.